Key Takeaways:
- McKesson (MCK) delivered Q4 FY2026 adjusted EPS of $11.69, beating the $11.60 consensus, while full-year EPS rose 49% to $38.38 and revenue climbed 12% to $403 billion.
- McKesson sold a 13% minority stake in its Medical-Surgical Solutions unit to Apollo Funds for $1.25 billion, unlocking capital while retaining full operational control of the division.
- MCK stock could rise from $754 to around $1,101 per share by March 2029, representing a near 46% total return.
- That implies an annualized return of around 14.2% per year, well above the threshold many long-term investors consider attractive.
What Happened?
McKesson Corporation (MCK) reported Q4 FY2026 adjusted EPS of $11.69, surpassing the $11.60 consensus estimate and capping a fiscal year in which full-year EPS rose 49% to $38.38. Revenue climbed 12% to $403 billion, driven by strong pharmaceutical distribution volumes and continued expansion of the company’s oncology specialty drug platform.
McKesson also guided for FY2027 profit slightly above consensus estimates, citing ongoing strength in drug distribution. Despite these results, the stock trades near $754, roughly 24% below its 52-week high of $999, reflecting investor uncertainty around regulatory and pricing risks.
McKesson sold a 13% minority stake in its Medical-Surgical Solutions unit to Apollo Funds for $1.25 billion, a transaction that validates the division’s standalone value while preserving McKesson’s operational control. The Medical-Surgical unit distributes supplies to physician offices, surgery centers, and long-term care facilities, a segment that benefits structurally from the aging U.S. population.
McKesson also signed a new $5 billion revolving credit facility with a JPMorgan-led bank group, extending its financial flexibility through 2031. Investors viewed the Apollo transaction as a positive capital allocation signal, as it unlocks value and provides McKesson with incremental resources for buybacks and reinvestment.
McKesson named Kenny Cheung, formerly the CFO of Sysco Corporation, as its new Chief Financial Officer following the announced retirement of Britt Vitalone. Leadership transitions can create short-term uncertainty, but Cheung’s experience managing large-scale distribution operations is viewed as directly relevant to McKesson’s business.
The company continues to invest in its oncology technology platform, which supports both drug distribution and clinical care coordination for cancer care providers. Investors are broadly optimistic about McKesson’s long-term trajectory but remain watchful of any potential shifts in pharmaceutical pricing policy or drug distribution reimbursement rules.
Here’s why McKesson stock could offer solid capital returns through 2031 as its core business drivers support shareholder value.
What the Model Says for MCK Stock
We analyzed the upside potential for McKesson stock based on its dominant position in pharmaceutical distribution, growing oncology specialty segment, and consistent EPS expansion through aggressive share buybacks and operational leverage.
Based on estimates of 7.4% annual revenue growth, 1.7% operating margins, and a normalized P/E multiple of 17.0x, the model projects McKesson stock could rise from $754 to around $1,101 per share.
That would be a near 46% total return, or a 14.2% annualized return over the next 2.8 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for MCK stock:
1. Revenue Growth: 7.4%
McKesson is the largest U.S. pharmaceutical distributor, serving hospitals, retail pharmacies, and specialty drug centers at scale. Revenue grew 12% in FY2026, driven by higher volumes and faster-growing oncology distribution with stronger economics.
Analysts expect McKesson revenue to grow in mid-single digits as drug spending rises with an aging U.S. population. Specialty and biologic drugs are the fastest-growing, and McKesson’s scale supports capturing incremental volume.
Based on analysts’ consensus estimates, we used 7.4% annual revenue growth. This reflects McKesson’s strong pharma volumes and specialty growth, offset by risks from drug pricing and reimbursement changes.
2. Operating Margins: 1.7%
McKesson’s operating margins are intentionally low at around 1.7% because pharmaceutical distribution is a high-volume, low-margin business by nature. The company earns small spreads on enormous drug volumes, making total operating profit highly sensitive to volume changes but relatively resilient to pricing pressure on individual drugs.
Historically, McKesson’s EBIT margins have remained in a narrow band between 1.5% and 1.7%, consistent with the industry structure for large-scale wholesale drug distributors. Scale, operational efficiency, and a proprietary distribution network are the primary competitive advantages that sustain margins at these levels.
Based on analysts’ consensus estimates, we used 1.7% operating margins. This is consistent with recent performance and reflects steady volume growth without assuming meaningful margin expansion. Cost efficiencies from McKesson’s technology investments in distribution logistics could provide modest upside to this assumption over time.
3. Exit P/E Multiple: 17x
McKesson currently trades at an NTM P/E of around 17x, which reflects its consistent EPS growth from share buybacks, operational leverage, and specialty drug volume gains. This multiple is reasonable for a large-scale distributor that generates predictable free cash flow and returns capital aggressively to shareholders.
Historically, McKesson has traded between roughly 14x and 20x earnings, and the current valuation sits in the middle of that historical range. The discount to the broader market reflects the low-margin nature of distribution and regulatory risk around pharmaceutical pricing reform.
Based on analysts’ consensus estimates, we used a 17.0x exit P/E multiple. This implies the multiple stays broadly stable as EPS growth from buybacks and specialty drug volumes drives price appreciation. A more aggressive capital return program or a favorable regulatory outcome could expand the multiples above this assumption.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for MCK stock through 2036 show varied outcomes based on pharmaceutical distribution volume growth, oncology specialty expansion, and drug pricing policy developments (these are estimates, not guaranteed returns):
- Low Case: Drug pricing regulation tightens, and specialty drug growth disappoints, slowing EPS expansion significantly → 6.4% annual returns
- Mid Case: Oncology distribution scales steadily and buybacks continue to drive consistent EPS growth → 9.5% annual returns
- High Case: Specialty drug volumes surge and McKesson gains meaningful market share across its distribution network → 12.3% annual returns
Going forward, McKesson’s near-term return potential of around 14.2% annually through March 2029 looks attractive relative to most large-cap peers, and even the longer-term mid-case projection of 9.5% annually through 2036 exceeds many fixed-income alternatives.
However, pharmaceutical pricing policy remains the most important variable for investors to monitor closely. Buyers who are comfortable with that regulatory risk may find the current valuation and earnings trajectory compelling.
See what analysts think about MCK stock right now (Free with TIKR) >>>
Should You Invest in McKesson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up MCK, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track MCK alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze the stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
